
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/573998/publications.pdf Version: 2024-02-01



FDITZ DIEKMANN

#	Article	IF	CITATIONS
1	Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?. American Journal of Transplantation, 2020, 20, 1875-1878.	2.6	240
2	Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. American Journal of Transplantation, 2021, 21, 2727-2739.	2.6	197
3	Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opinion on Drug Safety, 2016, 15, 303-319.	1.0	91
4	mTOR inhibitor–associated proteinuria in kidney transplant recipients. Transplantation Reviews, 2012, 26, 27-29.	1.2	65
5	Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients. American Journal of Transplantation, 2020, 20, 2958-2959.	2.6	65
6	Mucormycosis associated with COVIDâ€19 in two kidney transplantÂpatients. Transplant Infectious Disease, 2021, 23, e13652.	0.7	54
7	Mammalian Target of Rapamycin Inhibition Halts the Progression of Proteinuria in a Rat Model of Reduced Renal Mass. Journal of the American Society of Nephrology: JASN, 2007, 18, 2653-2660.	3.0	52
8	A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. PLoS ONE, 2021, 16, e0247251.	1.1	38
9	Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications. American Journal of Transplantation, 2019, 19, 123-131.	2.6	35
10	mTOR inhibition and erythropoiesis: microcytosis or anaemia?. Nephrology Dialysis Transplantation, 2012, 27, 537-541.	0.4	33
11	Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrology Dialysis Transplantation, 2007, 22, 2316-2321.	0.4	32
12	Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection. BMC Nephrology, 2018, 19, 261.	0.8	31
13	Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis. Transplant International, 2016, 29, 1216-1225.	0.8	27
14	Health-Related Quality of Life in People Across the Spectrum of CKD. Kidney International Reports, 2020, 5, 2264-2274.	0.4	25
15	COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?. Transplantation, 2021, 105, 2146-2155.	0.5	25
16	Outcomes of pancreas transplantation in older diabetic patients. BMJ Open Diabetes Research and Care, 2020, 8, e000916.	1.2	23
17	Histopathological evaluation of pretransplant donor biopsies in expanded criteria donors with high kidney donor profile index: a retrospective observational cohort study. Transplant International, 2017, 30, 975-986.	0.8	22
18	Urinary vitronectin identifies patients with high levels of fibrosis in kidney grafts. Journal of Nephrology, 2021, 34, 861-874.	0.9	20

#	Article	IF	CITATIONS
19	Sequential Quadruple Immunosuppression Including Sirolimus in Extended Criteria and Nonheartbeating Donor Kidney Transplantation. Transplantation, 2007, 84, 429-432.	0.5	15
20	Immunosuppressive minimization with mTOR inhibitors and belatacept. Transplant International, 2015, 28, 921-927.	0.8	15
21	Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology. Immunobiology, 2017, 222, 620-630.	0.8	15
22	The effect of differing kidney disease treatment modalities and organ donation and transplantation practices on health expenditure and patient outcomes. Nephrology Dialysis Transplantation, 2018, 33, 560-562.	0.4	15
23	A 2020 Banff Antibodyâ€mediatedInjury Working Group examination of international practices for diagnosing antibodyâ€mediated rejection in kidney transplantation – a cohort study. Transplant International, 2021, 34, 488-498.	0.8	15
24	Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients. Journal of Nephrology, 2022, 35, 769-778.	0.9	15
25	Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome. Kidney International Reports, 2018, 3, 926-938.	0.4	14
26	Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy. Brazilian Journal of Infectious Diseases, 2018, 22, 193-201.	0.3	13
27	Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice. Journal of Nephrology, 2020, 33, 601-610.	0.9	13
28	Sirolimus Monotherapy: Feasible Immunosuppression for Long-Term Follow-up of Kidney Transplantation???A Pilot Experience. Transplantation, 2005, 80, 1344-1348.	0.5	12
29	Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients. Transplantation Direct, 2016, 2, e69.	0.8	12
30	Recomendaciones para el uso de everolimus en trasplante renal de novo: falsas creencias, mitos y realidades. Nefrologia, 2017, 37, 253-266.	0.2	12
31	Uso terapéutico de las vesÃculas extracelulares en insuficiencia renal aguda y crónica. Nefrologia, 2017, 37, 126-137.	0.2	12
32	Should kidney allografts from old donors be allocated only to old recipients?. Transplant International, 2020, 33, 849-857.	0.8	12
33	Early intestinal complications following pancreas transplantation: lessons learned from over 300 cases – a retrospective singleâ€center study. Transplant International, 2021, 34, 139-152.	0.8	12
34	Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging. Transplant International, 2016, 29, 1008-1016.	0.8	11
35	Kidney Graft Outcomes in High Immunological Risk Simultaneous Liverâ€Kidney Transplants. Liver Transplantation, 2020, 26, 517-527.	1.3	11
36	Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19. Journal of Clinical Medicine, 2021, 10, 1551.	1.0	11

#	Article	IF	CITATIONS
37	mTOR Inhibition. Transplantation Direct, 2016, 2, e65.	0.8	10
38	An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI. Transplant International, 2016, 29, 362-368.	0.8	9
39	Pancreas outcomes between living and deceased kidney donor in pancreas after kidney transplantation patients. Nephrology Dialysis Transplantation, 2018, 33, 2052-2059.	0.4	9
40	The impact of functional delayed graft function in the modern era of kidney transplantation – A retrospective study. Transplant International, 2021, 34, 175-184.	0.8	9
41	A hybrid data envelopment analysis—artificial neural network prediction model for COVID-19 severity in transplant recipients. Artificial Intelligence Review, 2021, 54, 4653-4684.	9.7	9
42	Sirolimus in renal transplant recipients with malignancies in Germany. CKJ: Clinical Kidney Journal, 2021, 14, 2047-2058.	1.4	9
43	Treatment With Sirolimus Is Associated With Less Weight Gain After Kidney Transplantation. Transplantation, 2013, 96, 480-486.	0.5	8
44	Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice. Transplantation, 2020, 104, 1686-1694.	0.5	8
45	Results and Lessons Learned on Robotic Assisted Kidney Transplantation. BioMed Research International, 2020, 2020, 1-8.	0.9	8
46	IgA Nephropathy Recurrence after Kidney Transplantation: Role of Recipient Age and Human Leukocyte Antigen-B Mismatch. American Journal of Nephrology, 2020, 51, 357-365.	1.4	8
47	A case of recurrent anemia due to chronic parvovirus B19 infection in a kidney transplant recipient. Can everolimus make a difference?. CEN Case Reports, 2021, 10, 388-392.	0.5	8
48	Factors Associated With Advanced Colorectal Neoplasia in Patients With CKD. American Journal of Kidney Diseases, 2022, 79, 549-560.	2.1	8
49	Long-term mycophenolate monotherapy in human leukocyte antigen (HLA)-identical living-donor kidney transplantation. Transplantation Research, 2014, 3, 4.	1.5	7
50	Practical considerations for the use of mTOR inhibitors. Transplantation Research, 2015, 4, 13-17.	1.5	7
51	Borderline rejection in <scp>ABO</scp> â€incompatible kidney transplantation. Clinical Transplantation, 2016, 30, 872-879.	0.8	7
52	The development of a predictive model of graft function in uncontrolled donors after circulatory death: validity of a pulsatile renal preservation machine cut-off value for kidney acceptance. Nephrology Dialysis Transplantation, 2019, 34, 531-538.	0.4	7
53	Outcomes From Brain Death Donors With Previous Cardiac Arrest Accepted for Pancreas Transplantation. Annals of Surgery, 2021, 273, e230-e238.	2.1	7
54	Adoption of a novel smart mobileâ€health application technology to track chronic immunosuppression adherence in solid organ transplantation: Results of a prospective, observational, multicentre, pilot study. Clinical Transplantation, 2021, 35, e14278.	0.8	7

#	Article	IF	CITATIONS
55	Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. Clinical Immunology, 2021, 229, 108792.	1.4	6
56	BK Virus and Cytomegalovirus Coinfections in Kidney Transplantation and Their Impact on Allograft Loss. Journal of Clinical Medicine, 2021, 10, 3779.	1.0	6
57	Weight gain following pancreas transplantation in type 1 diabetes is associated with a worse glycemic profile: A retrospective cohort study. Diabetes Research and Clinical Practice, 2021, 179, 109026.	1.1	6
58	Outcomes after 20Âyears of experience in minimally invasive living-donor nephrectomy. World Journal of Urology, 2022, 40, 807-813.	1.2	6
59	Successful use of nonantigenâ€specific immunoadsorption with antihuman Igâ€columns in kidney graft antibodyâ€mediated rejection. Journal of Clinical Apheresis, 2020, 35, 188-199.	0.7	5
60	Taking care of kidney transplant recipients during the COVIDâ€19 pandemic: Experience from a medicalized hotel. Clinical Transplantation, 2021, 35, e14132.	0.8	5
61	Modeling patients as decision making units: evaluating the efficiency of kidney transplantation through data envelopment analysis. Health Care Management Science, 2021, 24, 55-71.	1.5	5
62	SARS-CoV-2 Infection After Full Vaccination in Kidney Transplant Recipients. Transplantation, 2021, 105, e278-e279.	0.5	5
63	Preemptive simultaneous pancreas kidney transplantation has survival benefit to patients. Kidney International, 2022, 102, 421-430.	2.6	5
64	Hepatitis C viremia as a risk factor for opportunistic infections in kidney transplant recipients. Clinical Transplantation, 2018, 32, e13382.	0.8	4
65	Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: A Report of 6 Cases. American Journal of Kidney Diseases, 2021, 78, 755-759.	2.1	4
66	Primary herpes simplex virus type 1 infection with acute liver failure in solid organ transplantation: Report of three cases and review. IDCases, 2022, 28, e01485.	0.4	4
67	B Cell-Derived Extracellular Vesicles Reveal Residual B Cell Activity in Kidney Graft Recipients Undergoing Pre-Transplant Desensitization. Frontiers in Medicine, 2021, 8, 781239.	1.2	4
68	A case of esophageal adenocarcinoma on long-term rapamycin monotherapy. Transplant International, 2015, 28, 1240-1244.	0.8	3
69	Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3â€year retrospective cohort study. Transplant Infectious Disease, 2017, 19, e12724.	0.7	3
70	The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation. CKJ: Clinical Kidney Journal, 2018, 11, 422-428.	1.4	3
71	Impact of Discards for Living Donor Kidney Transplantation in a Transplant Program. Transplantation Proceedings, 2019, 51, 3222-3226.	0.3	3
72	Increasing kidney grafts for transplantation. World Journal of Urology, 2021, 39, 2795-2800.	1.2	3

#	Article	IF	CITATIONS
73	Regulated Cell Death at the Crossroad Between Ischemia-reperfusion Injury and Innate Immunity in Kidney Transplantation. Transplantation, 2020, 104, 1772-1773.	0.5	3
74	Determinants of Successful Use of Sirolimus in Renal Transplant Patients. Transplantation Proceedings, 2020, 52, 3103-3111.	0.3	3
75	Immunogenic and immunotolerogenic effects of extracorporeal photopheresis in high immunological risk kidney recipients. A single center case series. Journal of Clinical Apheresis, 2022, 37, 197-205.	0.7	3
76	Current Trends in Organ Preservation Solutions for Pancreas Transplantation: A Single-Center Retrospective Study. Transplant International, 2022, 35, 10419.	0.8	3
77	Safety of hepatitis C virus (HCV)-treated donors for kidney transplantation excluding occult HCV infection through kidney biopsies. Transplant International, 2018, 31, 938-939.	0.8	2
78	Accelerated cellular rejection with prominent interstitial hemorrhage following cemiplimab treatment: How can we approach a renal transplant recipient under anti-PD1 therapy?. Journal of Onco-Nephrology, 2021, 5, 145-149.	0.3	2
79	Development of calciphylaxis in kidney transplant recipients with a functioning graft. CKJ: Clinical Kidney Journal, 2022, 15, 663-671.	1.4	2
80	Death of recipients after kidney living donation triples donors' risk of dropping out from follow-up: a retrospective study. Transplant International, 2017, 30, 603-610.	0.8	1
81	Postinfectious Acute Glomerulonephritis in Renal Transplantation: An Emergent Aetiology of Renal Allograft Loss. Case Reports in Transplantation, 2019, 2019, 1-4.	0.1	1
82	Donor insulin use during stay in the intensive care unit should not preclude pancreas transplantation. Diabetologia, 2021, 64, 2122-2123.	2.9	1
83	Overcoming limits: First ABO incompatible living donor paired kidney transplant in an hypersensitized pediatric recipient in Spain. Pediatric Transplantation, 0, , .	0.5	1
84	SP757COMBINATION OF CALCINEURIN INHIBITORS AND MTOR INHIBITORS FOLLOWING KIDNEY TRANSPLANTATION IN COMPARISON WITH MYCOPHENOLATE: EXPERIENCE FROM A REAL-LIFE SETTING. Nephrology Dialysis Transplantation, 2018, 33, i603-i604.	0.4	0
85	SP693SAFETY OF INDUCTION IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTATION: FOCUS ON 1-YEAR HOSPITALIZATIONS FOR INFECTION AND DEVELOPMENT OF POST-TRANSPLANT NEOPLASIA. Nephrology Dialysis Transplantation, 2018, 33, i580-i580.	0.4	0
86	SP767THROMBOTIC MICROANGIOPATHY RELATED TO KIDNEY TRANSPLANTATION:A MULTICENTRE RETROSPECTIVE STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
87	FP796IMPACT OF FUNCTIONAL DELAYED GRAFT FUNCTION IN THE MODERN ERA OF KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
88	Persistent fever due to acute pancreatic graftÂrejection. Kidney International, 2019, 96, 1242.	2.6	0
89	Do we still need to demonstrate the survival benefit of pancreas transplantation?. American Journal of Transplantation, 2019, 19, 1241-1242.	2.6	0
90	P1699EFFECT OF UREMIA IN THE POSTOPERATIVE OF PREEMPTIVE LIVING-DONOR KIDNEY TRANSPLANT PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0

#	Article	IF	CITATIONS
91	P1761SIDE EFFECTS OF MTOR INHIBITORS DEPEND ON THE BASELINE METABOLIC STATUS OF KIDNEY TRANSPLANT RECIPIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
92	P1840EVOLUTION OF FACTORS ASSOCIATED WITH THE DEVELOPMENT OF CALCIPHYLAXIS AFTER KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
93	Reply. Liver Transplantation, 2020, 26, 847-848.	1.3	0
94	¿Es la hiporrespuesta inmune de la uremia un factor de protección contra la neumonÃa grave por COVID-19?. Nefrologia, 2021, 41, 223-224.	0.2	0
95	MO926RAPID VS. LATE RE-TRANSPLANTATION FOR EARLY KIDNEY GRAFT LOSS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
96	Rapid reâ€ŧransplantation safety following early kidney graft loss. Nephrology, 2021, 26, 742-747.	0.7	0
97	406.2: Utility of Donor-derived Cell-free DNA in Assessing Simultaneous Pancreas-Kidney Transplantation Rejection. Transplantation, 2021, 105, S31-S31.	0.5	0
98	P.149: Extracellular Vesicles From Patients With Diabetic Nephropathy Induce Endothelial Dysfunction Through ICAM-1 and VCAM-1 in an In Vitro Model. Transplantation, 2021, 105, S61-S61.	0.5	0
99	P.136: Impact of Insulin Therapy in Pancreas Transplantation Donors on Graft Outcomes: An Analysis of the OPTN/UNOS Database. Transplantation, 2021, 105, S54-S54.	0.5	0
100	FC002: Humoral and Cellular Immune Responses After a Three-Dose Course of Mrna-1273 Covid-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
101	FC 110: Survival Benefit of Preemptive Simultaneous Pancreas-Kidney Transplantation. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	Ο